Email Alert RSS
Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
QUE Yongtu, LI Pengchong, ZHANG Fengchun. Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 196-202. DOI: 10.12290/xhyxzz.2022-0131
Citation: QUE Yongtu, LI Pengchong, ZHANG Fengchun. Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 196-202. DOI: 10.12290/xhyxzz.2022-0131
shu

Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases

  • 1.

    Department of Rheumatology and Immunology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Rheumatology and Immunology, Dongguan Kanghua Hospital, Dongguan, Guangdong 523000, China

More Information
  • Corresponding author:

    ZHANG Fengchun, E-mail: zhangfccra@aliyun.com

  • Received Date: March 19, 2022
  • Accepted Date: April 24, 2022
  • Issue Publish Date: January 29, 2023
    Graphical Abstract
    • Abstract
  • The incidence of the opportunistic infection of pneumocystis carini pneumonia(PCP) in patients with autoimmune diseases has increased over recent years, because of the use of glucocorticoids, immunosuppressants, small molecule targeted drugs and biological agents. This group of patients show more rapid progress and higher mortality than human immunodeficiency virus positive patients with PCP. Sulfonamide is the first-line treatment for PCP. Many scholars advocate taking trimethoprim-sulfamethoxazole(TMP-SMZ) for prophylaxis of PCP. However, the adverse effects of sulfonamides and drug resistance cannot be ignored. This article reviews the risk factors for the development of PCP in patients with autoimmune diseases, the effectiveness of PCP prevention with TMP-SMZ, and adverse drug reactions, tolerance, and drug resistance.
    • FullText(HTML)
    • References (57)
  • [1]
    Eddens T, Kolls JK. Pathological and protective immunity to Pneumocystis infection[J]. Semin Immunopathol, 2015, 37: 153-162. DOI: 10.1007/s00281-014-0459-z
    [2]
    Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review[J]. Clin Rheumatol, 2007, 26: 663-670. DOI: 10.1007/s10067-006-0441-9
    [3]
    Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii Pneumonia[J]. Infect Dis Clin North Am, 2010, 24: 107-138. DOI: 10.1016/j.idc.2009.10.010
    [4]
    Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases[J]. J Rheumatol, 1994, 21: 246-251.
    [5]
    Chen M, Tian X, Qin F, et al. Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death[J]. PLoS One, 2015, 10: e0139144. DOI: 10.1371/journal.pone.0139144
    [6]
    Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids[J]. Ann Rheum Dis, 2018, 77: 644-649. DOI: 10.1136/annrheumdis-2017-211796
    [7]
    Schmidt JJ, Lueck C, Ziesing S, et al. Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years[J]. Crit Care, 2018, 22: 307. DOI: 10.1186/s13054-018-2221-8
    [8]
    Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients[J]. Am J Med, 2014, 127: 1242. e11-e17.
    [9]
    Ishikawa Y, Nakano K, Tokutsu K, et al. Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases[J]. RMD Open, 2021, 7: e001508. DOI: 10.1136/rmdopen-2020-001508
    [10]
    Chew LC, Maceda-Galang LM, Tan YK, et al. Pneum-ocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid[J]. J Clin Rheumatol, 2015, 21: 72-75. DOI: 10.1097/RHU.0000000000000215
    [11]
    Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies[J]. Kansenshogaku Zasshi, 2014, 88: 26-39.
    [12]
    Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome[J]. Rheumatology (Oxford), 2011, 50: 569-577. DOI: 10.1093/rheumatology/keq314
    [13]
    Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?[J]. Arthritis Res Ther, 2009, 11: 253. DOI: 10.1186/ar2826
    [14]
    Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality[J]. Arthritis Rheum, 1999, 42: 780-789. DOI: 10.1002/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M
    [15]
    Matraiah EH, Olisaka N, Philipos M, et al. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis[J]. Clin Rheumatol, 2018, 37: 1991-1996. DOI: 10.1007/s10067-018-4155-6
    [16]
    Ghembaza A, Vautier M, Cacoub P, et al. Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases[J]. Chest, 2020, 158: 2323-2332. DOI: 10.1016/j.chest.2020.05.558
    [17]
    Lertnawapan R, Totemchokchyakarn K, Nantiruj K, et al. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus[J]. Rheumatol Int, 2009, 29: 491-496. DOI: 10.1007/s00296-008-0721-6
    [18]
    Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis[J]. Arthritis Rheum, 1997, 40: 2187-2198. DOI: 10.1002/art.1780401213
    [19]
    Blaas S. Pneumocystis jirovecii pneumonia in patients with autoimmune diseases[J]. Z Rheumatol, 2017, 76: 761-766. DOI: 10.1007/s00393-017-0390-5
    [20]
    Gupta D, Zachariah A, Roppelt H, et al. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature[J]. J Clin Rheumatol, 2008, 14: 267-272. DOI: 10.1097/RHU.0b013e31817a7e30
    [21]
    Redondo-Benito A, Curran A, Villar-Gomez A, et al. Opportunistic infections in patients with idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2018, 21: 487-496. DOI: 10.1111/1756-185X.13255
    [22]
    Viguier M Fouéré S, De La Salmonière P, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy[J]. Medicine (Baltimore), 2003, 82: 82-86. DOI: 10.1097/00005792-200303000-00002
    [23]
    Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases[J]. Dig Dis Sci, 2007, 52: 1481-1484. DOI: 10.1007/s10620-006-9250-x
    [24]
    Tanaka M, Sakai R, Koike R, et al. Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors[J]. Mod Rheumatol, 2012, 22: 849-858. DOI: 10.3109/s10165-012-0615-z
    [25]
    Rutherford AI, Patarata E, Subesinghe S, et al. Opportu-nistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis[J]. Rheumatology (Oxford), 2018, 57: 997-1001. DOI: 10.1093/rheumatology/key023
    [26]
    Raychaudhuri SP, Siu S. Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatolog-ical diseases[J]. Br J Dermatol, 1999, 141: 528-530. DOI: 10.1046/j.1365-2133.1999.03052.x
    [27]
    Wolfe RM, Peacock JE. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?[J]. Curr Rheumatol Rep, 2017, 19: 35. DOI: 10.1007/s11926-017-0664-6
    [28]
    Shams I, Ivory C, Cowan J. Duration of prednisone treatment before development of Pneumocystis jirovecii pneumonia in patients with vasculitis: A case series[J]. J Assoc Med Microbiol Infect Dis Can, 2022, 7: 117-124.
    [29]
    Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole[J]. Arthritis Res Ther, 2019, 21: 207. DOI: 10.1186/s13075-019-1996-6
    [30]
    Yeo KJ, Chen HH, Chen YM, et al. Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study[J]. BMC Infect Dis, 2020, 20: 112. DOI: 10.1186/s12879-020-4826-1
    [31]
    Besada E, Nossent JC. Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?[J]. Clin Rheumatol, 2013, 32: 1677-1681. DOI: 10.1007/s10067-013-2293-4
    [32]
    Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients[J]. Arthritis Rheum, 2009, 61: 305-312. DOI: 10.1002/art.24283
    [33]
    Inokuma S. Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate[J]. Expert Opin Drug Saf, 2021, 21: 573-580.
    [34]
    Ohmura SI, Homma Y, Masui T, et al. Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study[J]. Intern Med, 2021, 61: 997-1006.
    [35]
    唐晓艳, 李冀, 董芬, 等. 儿童系统性红斑狼疮并发卡氏肺孢子虫肺炎临床分析[J]. 中华儿科杂志, 2013, 51: 920-924. DOI: 10.3760/cma.j.issn.0578-1310.2013.12.008
    [36]
    Kageyama T, Furuta S, Ikeda K, et al. Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases[J]. PLoS One, 2019, 14: e0214324. DOI: 10.1371/journal.pone.0214324
    [37]
    Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population[J]. Ann Pharmacother, 2016, 50: 673-679. DOI: 10.1177/1060028016650107
    [38]
    Messiaen PE, Cuyx S, Dejagere T, et al. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review[J]. Transpl Infect Dis, 2017. doi: 10.1111/tid.12651.
    [39]
    刘颜岗, 赵菲璠, 周庆涛, 等. 人类免疫缺陷病毒阴性重症肺孢子菌肺炎患者的临床特征分析[J]. 国际呼吸杂志, 2021, 41: 1126-1131. DOI: 10.3760/cma.j.cn131368-20201224-01172
    [40]
    Nickel P, Schürmann M, Albrecht H, et al. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients[J]. Infection, 2014, 42: 981-989. DOI: 10.1007/s15010-014-0660-y
    [41]
    Ramos A. Infections in the immunocompromised host. What is the role of the medications?[J]. Reumatol Clin, 2008, 4: 1-6.
    [42]
    Wolfe RM, Beekmann SE, Polgreen PM, et al. Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: A Survey of Infectious Disease Physicians[J]. Open Forum Infect Dis, 2019, 6: ofz315. DOI: 10.1093/ofid/ofz315
    [43]
    Utsunomiya M, Dobashi H, Odani T, et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial[J]. Arthritis Res Ther, 2017, 19: 7. DOI: 10.1186/s13075-016-1206-8
    [44]
    Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases[J]. Semin Arthritis Rheum, 2011, 41: 497-502. DOI: 10.1016/j.semarthrit.2011.05.004
    [45]
    Kimura M, Tanaka S, Ishikawa A, et al. Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease[J]. Rheumatol Int, 2008, 28: 673-676. DOI: 10.1007/s00296-007-0505-4
    [46]
    Harada T, Kato R, Sueda Y, et al. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophy-laxis of Pneumocystis pneumonia in patients with rheumatic diseases[J]. Mod Rheumatol, 2021, 31: 629-635. DOI: 10.1080/14397595.2020.1812834
    [47]
    Classen AY, Henze L, Von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)[J]. Ann Hematol, 2021, 100: 1603-1620. DOI: 10.1007/s00277-021-04452-9
    [48]
    Kawato R, Rokutanda R, Okada M, et al. Effect of Prophylactic Dose of Trimethoprim-Sulfamethoxazole on Serum Creatinine in Japanese Patients With Connective Tissue Diseases[J]. Clin Med Insights Arthritis Musculoskelet Disord, 2022, 15: 11795441221085141.
    [49]
    Otani T, Yamaguchi K, Sakamoto S, et al. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study[J]. Pulm Pharmacol Ther, 2021, 67: 101999. DOI: 10.1016/j.pupt.2021.101999
    [50]
    Maezawa R, Kurasawa K, Arai S, et al. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for P. jiroveci pneumonia, in patients with connective tissue diseases[J]. Mod Rheumatol, 2013, 23: 62-70. DOI: 10.3109/s10165-012-0625-x
    [51]
    Pereda CA, Nishishinya-Aquino MB, Brito-García N, et al. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?[J]. Rheumatol Int, 2021, 41: 1419-1427. DOI: 10.1007/s00296-021-04808-4
    [52]
    Jinno S, Akashi K, Onishi A, et al. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids[J]. Rheumatol Int, 2021, 42: 1403-1409.
    [53]
    王梦嫣, 朱彪. 耶氏肺孢子菌对磺胺类药物耐药相关基因突变的研究进展[J]. 浙江大学学报(医学版), 2017, 46: 563-569. DOI: 10.3785/j.issn.1008-9292.2017.10.18
    [54]
    Ponce CA, Chabé M, George C, et al. High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy[J]. Antimicrob Agents Chemother, 2017, 61: e01290-e01316.
    [55]
    Montesinos I, Delforge ML, Ajjaham F, et al. Evaluation of a new commercial real-time PCR assay for diagnosis of Pneumocystis jirovecii pneumonia and identification of dihydropteroate synthase (DHPS) mutations[J]. Diagn Microbiol Infect Dis, 2017, 87: 32-36.
    [56]
    Hauser PM, Nahimana A, Taffe P, et al. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations[J]. Clin Infect Dis, 2010, 51: e28-e33.
    [57]
    Esteves F, Gaspar J, Marques T, et al. Identification of relevant single-nucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data[J]. Clin Microbiol Infect, 2010, 16: 878-884.
    • Related Articles

  • Related Articles

    [1]JIA Chunyu, WANG Gangan, WANG Jiahui, CHEN Gang, ZHENG Ke, LI Xuemei. Correlation Between Neutrophil to Lymphocyte Ratio and eGFR in Diabetic Patients: A Cross-sectional Analysis Based on NHANES Data[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 379-385. DOI: 10.12290/xhyxzz.2024-0908
    [2]TIAN Kunling, CHEN Chuanning. Notch Signaling Pathway and Congenital Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 649-654. DOI: 10.12290/xhyxzz.2023-0594
    [3]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [4]QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023
    [5]JIANG Xu, YANG Huaxia, ZHANG Fengchun. The Role of the Gut Microbial Metabolites in Autoimmune Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 747-752. DOI: 10.12290/xhyxzz.2022-0246
    [6]ZHAO Lidan, MENG Xia, XU Haojie, ZHANG Fengchun. Prospect of Gut Microbiota-based Intervention in Autoimmune Disease Control[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 740-746. DOI: 10.12290/xhyxzz.2022-0245
    [7]Xiao-yun ZHANG, Jian-yu HAO. PTEN and Digestive Organ Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 300-304. DOI: 10.3969/j.issn.1674-9081.2017.05.020
    [10]Jun-feng ZHEN, Song-bai LIN, Yang YU, Meng-zhao WANG. Pneumocystis Carinii Pneumonia in Ectopic Adrenocorticotrophic Hormone Syndrome: A Case Report and Literature Review[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 437-441. DOI: 10.3969/j.issn.1674-9081.2015.06.008

  • Cited by

    Periodical cited type(4)

    1. 俞利，刘楠. 心脏外科手术后右心衰竭诊断方法研究进展. 中国医药. 2024(09): 1402-1406 .
    2. 王燚，陈建淑，张小卫. 右心室-肺动脉耦合在心血管疾病中的临床应用进展. 心血管病学进展. 2024(09): 773-777+786 .
    3. 谢洪燕，刘东婷，刘家祎，赵文婧，汤泽辉，许妍，温兆赢. 心脏磁共振在肺动脉高压的应用与研究进展. 心肺血管病杂志. 2023(09): 974-978 .
    4. 何琳琳，冯德喜. 应用无创性压力-应变环定量评价重度动脉性肺动脉高压患者早期左心室功能. 中国医师杂志. 2023(12): 1824-1828 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (538) PDF downloads (129) Cited by(5)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close